Vactech Oy
Diagnostics

Patented Diagnostics for Early Disease Prevention

Vactech holds patented innovations for reliably detecting enteroviruses linked to type 1 diabetes and celiac disease. Our diagnostics identify at-risk individuals early, paving the way for targeted antiviral interventions.
Read More

Patented Innovations

Advancing Accurate Diagnostics and Preventive Care

Our patented technology enables the precise detection of enterovirus infections associated with the development of type 1 diabetes and celiac disease. Accurate and early diagnosis allows for personalized antiviral treatments aimed at preventing or halting disease progression, improving health outcomes and quality of life for at-risk individuals.

Ask for more

Career Opportunities

At Vactech, Innovation Meets Impact.
Join Us in Reshaping Global Health.

Join our team

 

 

About Vactech

Vactech is a company with a pipeline of product candidates focused on type 1 diabetes, celiac disease, and diagnostics. The primary focus of our research and product development is to unravel and treat the complexities of immune-mediated diseases and enteroviruses.

Read more
Latest News and Press Releases

New Insights into the Role of Enteroviruses in Type 1 Diabetes

Vactech Appoints Dr. Tero Välimaa as New Chief Executive Officer

The results of the PRV-101 vaccine Phase I trial published in Diabetologia.

Read all
Contact Us

Vactech Oy
Biokatu 8
33520 Tampere, Finland

Privacy Policy